1.	A Study in Second Line Metastatic Colorectal Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 13856, I4T-MC-JVBB, CP12-0920, 2010-021037-32, CTRI/2011/07/001900, NCT01183780
2.	A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 13916, I4T-IE-JVBL, CP12-0917, 2009-016784-11, NCT01160744
3.	Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 13943, CP20-0902, I4Y-IE-JCDC, NCT01282463
4.	A Study to Assess the Pharmacokinetics of Ramucirumab in Combination With FOLFIRI Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 14433, CP12-1033, I4T-IE-JVCB, NCT01634555
5.	A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Active Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 14658, I4T-JE-JVCG, NCT01703091
6.	A Study in Participants With Advanced Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 14139, I4T-CR-JVBU, NCT01682135